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Abstract
Hypoxia-induced pulmonary hypertension (HPH) is a progressive disease that is mainly caused by chronic exposure to high altitude,
chronic obstructive lung disease, and obstructive sleep apnea. The increased pulmonary vascular resistance and increased pulmonary
arterial pressure result in increased right ventricular afterload, leading to right heart failure and increased morbidity. There are several
clinical reports suggesting a link between PH and diabetes, insulin resistance, or obesity; however, it is unclear whether HPH is
associated with diabetes as a progressive complication in diabetes. The major goal of this study is to examine the effect of diabetic
‘‘preconditioning’’ or priming effect on the progression of HPH and define the molecular mechanisms that explain the link between
diabetes and HPH. Our data show that HPH is significantly enhanced in diabetic mice, while endothelium-dependent relaxation in
pulmonary arteries is significantly attenuated in chronically hypoxic diabetic mice (DH). In addition, we demonstrate that mouse
pulmonary endothelial cells (MPECs) isolated from DH mice exhibit a significant increase in mitochondrial reactive oxygen species
(ROS) concentration and decreased SOD2 protein expression. Finally, scavenging mitochondrial ROS by mitoTempol restores
endothelium-dependent relaxation in pulmonary arteries that is attenuated in DH mice. These data suggest that excessive mito-
chondrial ROS production in diabetic MPECs leads to the development of severe HPH in diabetic mice exposed to hypoxia.
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In the USA, more than 29 million people suffer from dia-
betes and 1.7 million people, aged 20 years or older, are
newly diagnosed with diabetes every year. Diabetes is the
seventh leading cause of death and nearly 65% of patients
with diabetes die from cardiovascular diseases. Because of
such a large diabetic population, many diabetic patients
living in areas of high altitudes or having hypoxic lung dis-
eases (e.g. chronic obstructive pulmonary disease [COPD])
and obstructive sleep apnea (OSA) might be exposed to
sustained hypobaric hypoxia (in high altitudes), regional
alveolar hypoxia (due to COPD), and intermittent hypoxia
(as a result of OSA).
Hypoxia is a major cause for pulmonary hypertension
(PH). Hypoxia-induced pulmonary hypertension (HPH) or
PH associated with hypoxic lung diseases is categorized as
World Health Organization (WHO) Group III of PH and is
mainly associated with chronic exposure to high altitudes,
chronic obstructive lung disease (e.g. COPD), and OSA. The
first clinical report that documented the link between dia-
betic mellitus (DM) and PH was published in 2005.1
Mavahed et al. showed that patients with DM exhibited a
significantly higher prevalence of PH than in non-diabetic
patients. Later, Makarevich et al. demonstrated that mean
pulmonary arterial pressure (PAP) was significantly higher
in patients with DM and COPD than in patients with
COPD alone.2 Pugh et al. reported that PH patients with
higher HbA1c (>6.0%) showed shorter 6-minute walk
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distance (a method to assess the disease condition and ther-
apeutic outcome in PH patients) compared to PH patients
with <6.0% HbA1c.3 The survival rate in PH patients with
DM was also worse than in PH patients without DM.4,5
These data clearly indicate that there is a strong correlation
between DM and the progression or severity of PH. The
molecular mechanisms to increase the susceptibility to the
hypoxia in diabetes are, however, not revealed.
Vascular endothelial cells play an important role in the reg-
ulation of vascular tone and formation of new vessels.
Vasoconstriction and vasodilatation are regulated by the
endothelium via secretion of endothelium-derived constricting
factors (e.g. thromboxane A2 and endothelin-1) and endothe-
lium-derived relaxing factors (e.g. nitric oxide [NO], prostacy-
clin [PGI2], and endothelium-derived hyperpolarizing factors
[EDHF]). Endothelium-dependent hyperpolarization (EDH)
is also an important mechanism that leads to endothelium-
dependent vasodilation. It is well demonstrated that the
endothelium is dysfunctional in diabetes6–9 and the endothe-
lium-dependent relaxation (EDR) is attenuated due to the
decrease in NO bioavailability10–13 and/or impaired EDH-
induced relaxation.14–16 Pulmonary endothelial dysfunction is
also implicated in the development and progression of PH.17–19
Therefore, pulmonary vascular endothelial dysfunction asso-
ciated with diabetes would inhibit pulmonary EDR, which sub-
sequently results in sustained vasoconstriction and ultimately
increases pulmonary vascular resistance (PVR) and PAP.
Under physiological conditions, ECs constantly generate
reactive oxygen species (ROS), including superoxide anion
(O2
), that participate in modulation of essential endothe-
lial functions. The imbalance between production and elim-
ination of ROS results in increased oxidative stress and
tissue injury, and leads to many cardiovascular diseases.
The putative sources of O2
 include mitochondrial respira-
tory chain,20 uncoupled eNOS,21 NADPH oxidases,22 and
xanthine oxidase. It has been reported that altered mito-
chondrial O2
 concentration ([O2
]mito) is involved in
endothelial dysfunction in diabetes12,23–28 and PH;29–33 how-
ever, there is no report investigating the mitochondrial ROS
concentration ([ROS]mito) under both hypoxia and diabetic
conditions. In this study, we demonstrate that diabetic mice
are more susceptive to hypoxia to develop severe PH com-
pared to non-diabetic mice. It is, at least in part, caused by
increased [ROS]mito in pulmonary endothelial cells and
decreased endothelium-dependent pulmonary vasodilation
in diabetic mice under hypoxia. Our data imply that diabetic
patients who live in the high altitude, suffer from hypoxic
respiratory diseases like COPD or have OSA might have a
higher risk of developing severe PH.
Methods
Biological materials and reagents
M199, antibiotic reagents, dispase II, and MitoSOX Red
were purchased from Thermo Fisher Scientific Inc.
(Rockford, IL, USA). Streptozotocin and anti-superoxide
dismutase 2 (SOD2) antibody were obtained from Enzo
Life Science (Plymouth Meeting, PA, USA). Anti-actin anti-
body and mitoTempol (mitoT) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-CD31
and endothelial cell growth supplement (ECGS) were pur-
chased from BD Biosciences (San Jose, CA, USA).
Collagenase II was from Worthington Biochemical
(Lakewood, NJ, USA), and Microfil compound (yellow)
was purchased from Flowtech Inc. (South Windsor, CT,
USA). All other chemicals were obtained from Sigma-
Aldrich (St Louis, MO, USA).
Animal experiment
This animal study was conducted in accordance with the
guidelines established by the Institutional Animal Care
and Use Committee (IACUC) at the University of
Arizona. All animal use is in compliance with all current
US government regulations concerning the care and use of
laboratory animals. The University of Arizona has been
certified (Animal Welfare Assurance #A3248-01) and the
approved protocol number for this study is #14-520. The
laboratory personnel who conducted the following animal
experiments took all training courses required for animal
handling and were certified by the IACUC. All surgery
was performed under anesthesia with a mixture of ketamine
(100mg/kg, i.p.) and xylazine (5mg/kg, i.p.), and all efforts
were made to minimize suffering.
Male C57BL/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Inducible type 2 dia-
betic (T2D) mice were generated by a single injection of
streptozotocin (STZ, 75mg/kg, dissolved in citrate buffer,
i.p.) at the age of 6 weeks, and given a high fat diet (HF,
60% kcal) from the day of the STZ injection.34,35
Genetically modified T2D mice (KK.Cg-Ay/a mice: KK
mice) were purchased from the Jackson Laboratory and
bred in-house. For HPH mouse experiments, mice were
exposed to hypoxia (10% O2) in a ventilated chamber for
four weeks to develop PH.
Oral glucose tolerance test (OGTT)
OGTT was performed as described previously.34,36 Briefly,
mice were fasted for 6 h before the OGTT. Glucose (2 g/kg
bwt) was administrated orally and plasma glucose concen-
tration was measured at time 0 (before glucose administra-
tion), 15, 30, and 60min after glucose administration.
Right ventricle systolic pressure (RVSP) measurement
After mice were anesthetized, a catheter was inserted into
the right external jugular vein. Right ventricular pressure
(RVP) was measured and recorded using a MPVS Ultra
system (Millar Instruments) as described in our previous
manuscript.37 RVSP was calculated and compared between
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control and diabetic mice. We also calculated the change of
RVSP (normalized data by normoxia control [DN-CN, CH-
CN, DH-CN]).
Lung angiograph
Pulmonary angiography was conducted to visualize the pul-
monary vascular tree in the mouse lung using Microfil. The
lungs were perfused with 0.5mL/min Microfil for 2min
through the pulmonary artery (PA) and fixed at 4C for
overnight. Then the lungs filled with Microfil were bathed
in serial concentrations of ethanol, placed in methyl salicy-
late, and photographed with a digital camera (MD600E,
Amscope, Irvine, CA, USA). We made binary images
using NIH ImageJ 1.48v software on the peripheral pulmon-
ary vasculature (the areas between the edge of the lung and
1mm inside from the edge of the lung) using Photoshop CS
software; the images were then skeletonized for analyzing
the number of vessel branches, the number of junctions,
and the total length. These data were normalized by the
area selected in each lung image.
Isometric tension measurement in isolated PA ring
Isometric tension was measured as previously described.36
The lung was isolated and placed in Krebs-Henseleit solu-
tion for dissection. The third-order small PAs were dissected
out of the lung; attached fat and adherent connective tissues
were then removed from the isolated PA rings. The PA rings
were cut into 1–1.5-mm long segments. Rings were mounted
on a wire myograph with stainless wires of 20 mm in dia-
meter; the resting tension of the isolated PA ring was set
at 100mg (DMT-USA, Inc.). All PA rings set at the resting
tension were equilibrated for 45 min with intermittent
washes every 15min. After equilibration, each PA ring
was precontracted by application of PGF2a, and the
degree of ACh-induced vasodilatation was described as a
percentage (%) decrease of PGF2a-induced contraction.
Isolation of mouse pulmonary endothelial cells (MPEC)
MPECs were isolated as previously described.36 Briefly, dis-
sected lung tissues were minced and incubated in M199 con-
taining 2mg/mL collagenase I and 0.6 U/mL dispase II for
1 h at 37C. The digested material, including single cells and
pieces of tissue, was filtered through sterile 70-mm nylon mesh
and washed in M199 containing 2% fetal calf serum. The
remaining cells were then incubated with Dynabeads
(Invitrogen) coated with CD31 antibody. The Dynabeads
were prepared as follows: beads coated with sheep anti-rat
antibody were incubated with purified rat anti-mouse CD31
monoclonal antibody (1mg/mL) at 4C overnight and then
washed with PBS containing 0.1% BSA and 2mM EDTA.
Cell suspension was incubated with the CD31 antibody-
coated beads for 1 h at 4C and then beads attached to
endothelial cells were captured by Dynal magnet (Invitrogen).
Measurement of mitochondrial ROS concentration
[ROS]mito was measured as described previously.
24,38
Mitochondrial ROS was detected by preloading the cells
with 5 mmol/L of MitoSOX Red (mitochondrial ROS indi-
cator) for 30min. MitoSOX fluorescence from the cells were
imaged using a Nikon Eclipse Ti-E inverted fluorescence
microscope with 60 objective lens. The fluorescence inten-
sity of the MitoSOX in the mitochondria was measured and
the background intensity was subtracted from the cell
intensity.
Western blot analysis
Isolated MPECs were lysed and centrifuged at 16,000 g for
10min at 4C. Protein samples from ECs were separated
through a SDS-polyacrylamide gel and transferred to the
membranes. Blots were incubated with a primary antibody
(anti-SOD2 [1:1000] or anti-actin [1:4000]) followed by incu-
bation with a HRP-conjugated secondary antibody. The
immunoblots were detected with Super Signal West Pico
reagent (Thermo Fisher Scientific Inc. Rockford, IL,
USA). Band intensity was normalized to actin control and
expressed in arbitrary units.
Statistical analysis
The data are expressed as means standard error (SEM).
Differences between groups were analyzed for statistical sig-
nificance using Student’s t-test and post-hoc ANOVA.
Differences were considered to be statistically significant
when a P value was less than 0.05 (P< 0.05).
Results
Effect of chronic hypoxia exposure on OGTT and RVSP in
inducible T2D mice
To examine whether chronic hypoxia differentially affects
control and diabetic mice, we used two different diabetic
models: (i) inducible T2D mice (Fig. 1); and (ii) genetically
modified T2D (KK mice) (Fig. 2). Fig. 1a shows the time
course of the experiments in inducible T2D mice. There were
four groups of mice in the experiments: (i) control normoxia
(CN) mice; (ii) diabetic normoxia (DN) mice; (iii) control
hypoxia (CH) mice; and (iv) diabetic hypoxia (DH) mice. In
all groups of mice, we conducted the experimental measure-
ment (e.g. OGTT, RVSP) 16 weeks after initial grouping. In
the CN group, the mice were injected with vehicle at the age
of 6 weeks and housed in the same room as other mice under
normoxic conditions for 16 weeks before the experiment. In
the DN group, the mice were injected with STZ and fed with
a HF diet at the age of 6 weeks and housed under normoxic
conditions for 16 weeks before the experiment. In control
hypoxia (CH) group, mice were placed in a normobaric
hypoxic chamber at the age of 18 weeks and exposed to
hypoxia (10% O2) for 4 weeks before the experiment.
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Fig. 1. Inducible T2D mice exhibit higher levels of RVSP than control mice during normoxia and hypoxia-induced increase in RVSP is more
prominent in T2D mice compared to control mice. (a) Proposed experimental groups and protocols in mice. CN, control normoxia; DN, diabetic
normoxia; CH, control hypoxia; DH, diabetic hypoxia. (b) Oral glucose tolerance test. T2D mice exhibit abnormal glucose tolerance curve under
normoxia and hypoxia. CN, n¼ 10; DN, n¼ 10; CH, n¼ 7; DH; n¼ 7. Data are mean SEM. *P< 0.05 vs. control mice. (c) Body weight. Hypoxia
exposure decreases body weight in T2D mice. CN, n¼ 10; DN, n¼ 10; CH, n¼ 7; DH; n¼ 7. Data are mean SEM. *P< 0.05 vs. DN. (d) RVSP.
CN, n¼ 4; DN, n¼ 4; CH, n¼ 5; DH; n¼ 5. Data are mean SEM. *P< 0.05 vs. control mice. (e). Change in RVSP. CN, n¼ 4; DN, n¼ 4; CH,
n¼ 5; DH; n¼ 5. Data are mean SEM. *P< 0.05 vs. control mice.
Fig. 2. Chronic hypoxia-exposure increases RVSP in genetically modified type 2 mice (KK mice) greater than in wild-type mice. (a) Proposed
experimental groups and protocols in mice. Wild-type normoxia (WN), KK mice normoxia (KN), wild-type hypoxia (WH), and KK mice hypoxia
(KH). (b) Oral glucose tolerance test. Hypoxia decreased fasting glucose levels in both wild-type and KK mice; however impaired glucose
tolerance still remains in KK mice. WN, n¼ 5; KN, n¼ 5; WH, n¼ 5; KH, n¼ 4. Data are mean SEM. *P< 0.05 vs. wild-type mice. (c) Body
weight. Mice exposed to hypoxia exhibit lower body weight than mice under normoxia. WN, n¼ 5; KN, n¼ 5; WH, n¼ 5; KH, n¼ 4. Data are
mean SEM. *P< 0.05 vs. WN, #P< 0.05 vs. KN. (d) RVSP. n¼ 6 per group. Data are mean SEM. *P< 0.05 vs. wild-type mice. (e) Change in
RVSP. n¼ 6 per group. Data are mean SEM. *P< 0.05 vs. wild-type mice.
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In the DH group, the mice were injected with STZ and fed
with a HF diet at the age of 6 weeks, placed in a normobaric
hypoxic chamber at 12 weeks after induction of diabetes,
and exposed to hypoxia (10% O2) for 4 weeks before the
experiment.
In control normoxia (CN) mice, glucose tolerance curves
showed a normal decline in plasma glucose 30min after initial
glucose intake (at 0min) (Fig. 1b, open circles), whereas in
diabetic normoxia (DN) mice, glucose tolerance was signifi-
cantly attenuated as shown in the glucose tolerance curve in
which the decline phase of the plasma glucose after 30min
was almost plateaued indicating a significant impaired glu-
cose tolerance (Fig. 1b, closed circles). Hypoxic exposure
decreased the fasting glucose levels in both control (open
triangles) and T2D (closed triangles) groups (Fig. 1b); how-
ever, T2D mice still developed impaired glucose tolerance
under hypoxic condition. Hypoxia significantly decreased
body weight in T2D, but not in control mice (Fig. 1c).
In comparison to CN mice, DN mice exhibited a slight, but
statistically significant, increase in RVSP under normoxic con-
ditions (Fig. 1d and 1e, left panel). Under hypoxic conditions,
however, the hypoxia-induced increase in RVSP was signifi-
cantly enhanced in DH mice compared to CH mice (Fig. 1d
and 1e, right panel). These data provide strong evidence that
the severity of chronic hypoxia-induced PH is significantly
enhanced in diabetic mice; the enhanced HPH is associated
with an impaired glucose tolerance in diabetic mice.
Effect of chronic hypoxia exposure on OGTT and RVSP in
KK mice
To further confirm that HPH is enhanced in diabetic mice,
we repeated the experiments shown in Fig. 2 using a geneti-
cally modified T2D mouse model, the KK mice. Fig. 2a
shows the time course of the experiment. In the wild-type
(WT) normoxia (WN) group, the mice were housed under
normoxic conditions for 10 weeks before experimentation.
In the genetically modified diabetic (KK) normoxia (KN)
group, the mice were housed in the same room as WN mice
under normoxic conditions for 10 weeks before the experi-
ment. In the WT hypoxia (WH) group, mice were placed in
a normobaric hypoxic chamber at the age of 6 weeks and
exposed to hypoxia (10% O2) for 4 weeks before experimen-
tation. In the KK hypoxia (KH) group, the mice were
placed in a normobaric hypoxic chamber at the age of 6
weeks and exposed to hypoxia (10% O2) for 4 weeks
before experimentation (Fig. 2a).
In WT normoxia (WN) mice, the plasma glucose declined
rapidly 30min after initial intake of glucose (Fig. 2b, open
circles), whereas in genetically modified diabetic (KK) nor-
moxia mice (KN), the glucose tolerance was impaired as
shown by the significantly inhibited glucose decline in
blood (Fig. 2b, closed circles). Hypoxic exposure signifi-
cantly decreased the fasting glucose levels in both WH and
KH mice. However, there was a significant difference of
glucose tolerance between WH and KH mice after exposure
to hypoxia (Fig. 2b). Hypoxic exposure significantly
decreased body weight in both control and diabetic mice
(Fig. 2c).
In comparison to WN mice, KN mice exhibited a signifi-
cantly higher RVSP (approximately 30% increase) (Fig. 2d
and 2e, left panel). The hypoxia-induced increase in RVSP
was significantly enhanced in KH mice than in WH mice
(Fig. 2d and 2e, right panel). Consistent with the data shown
in the inducible T2D mice, these data further demonstrate that
hypoxia-induced PH is significantly enhanced in diabetes. The
enhanced HPH in diabetic mice may result from unique func-
tional and structural changes in PAs due to diabetes.
Hypoxic exposure occludes small branches in control and
T2D mice
Pulmonary vascular remodeling characterized by concentric
pulmonary arterial wall thickening and intraluminal oblitera-
tion is a major cause for the increased PVR and PAP. A
decrease in vascular density revealed by pulmonary angiogra-
phy has been implicated in patients with idiopathic pulmonary
arterial hypertension and in animals with experimental PH. To
investigate whether the structural change in the pulmonary
vasculature is involved in the enhanced HPH in diabetic
mice, we compared the lung angiograms taken from the
whole lungs of CN, DN, CH, and DH mice. Contrary to
our expectation, the lung angiography data showed that pul-
monary vascular density, determined by the numbers of vas-
cular branch and junction and the total vascular length, was
actually increased in DN mice in comparison to CN mice (Fig.
3a and 3b). Chronic exposure to hypoxia, however, signifi-
cantly decreased the numbers of vascular branch and junction
and the total vascular length in both control (CH) and diabetic
(DH) mice (Fig. 3a and 3b). Although the numbers of vascular
branch and junction and the total vascular length in CH and
DH mice were the same under hypoxic conditions, the differ-
ence between DH mice and DN mice was significantly greater
than the difference between CH mice and CN mice (Fig. 3c).
These data suggest that chronic exposure to hypoxia can sig-
nificantly reduce the pulmonary vascular density determined
by lung angiography in both control and diabetic mice; how-
ever, the hypoxia-induced decrease in lung vascular density
was significantly greater in diabetic mice than in control
mice. Pulmonary vascular remodeling due to concentric vas-
cular wall thickening and sustained pulmonary vasoconstric-
tion due to inhibited EDR in PAs both contribute to decreased
lung vascular density shown in lung angiograms. The next set
of experiments was designed to determine whether inhibited
EDR and mitochondrial ROS production are associated with
the severe HPH in diabetic mice.
Scavenging mitochondrial O2
– increases EDR in PAs of
DH but not in PAs of CH
EDR in PAs and arterioles is an important mechanism
involved in maintaining low PVR and PAP under normal
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and physiological conditions. EDR is mainly caused by the
production and release of the endothelium-derived relaxing
factor (EDRF), such as NO or prostacyclin (PGI2), and via
the induction of endothelium-dependent hyperpolarization.
To examine whether inhibited EDR contributes to the
enhanced HPH in diabetes, we compared the EDR in PA
rings isolated from control and diabetic mice under hypoxic
conditions. As shown in Fig. 4a, high Kþ-mediated pulmon-
ary vasoconstriction or increase in isometric tension in iso-
lated PA rings, mainly due to membrane depolarization-
induced opening of voltage-gated Ca2þ channels in PA
smooth muscle cells, was comparable in CH mice and DH
mice. These data suggest that the electromechanical cou-
pling-induced contraction in isolated PA rings from control
and diabetic mice was not affected by chronic hypoxia.
However, the ACh-induced EDR was significantly attenu-
ated in PA rings isolated from DH mice in comparison to
the rings isolated from CH mice (Fig. 4b).
Mitochondrial ROS production has been implicated
in the pulmonary arterial functions.39–41 Pretreatment of
mitoTempol (mitoT, 10 mM), a mitochondrial O2
–
scavenger, had a negligible effect on ACh-induced EDR in
PA rings isolated from CH mice (Fig. 4c), but exhibited
significantly enhanced EDR in PA rings isolated from DH
mice (Fig. 4d). These data indicate that chelation of mito-
chondrial ROS is able to enhance ACh-induced EDR in PA
rings from DH mice to the level similar to the EDR in PA
rings isolated from CH mice. Given the results showing that
mitoT (10 mM) had no effect on EDR in PA rings isolated
from CH mice, these results imply that the excessive produc-
tion of mitochondrial O2
– attenuates PA relaxation in DH
mice.
MPECs from DH exhibits increased mitochondrial ROS
concentration and decreased SOD2 protein expression
Since mitoT treatment increased EDR in PA rings isolated
from DH mice, we then expected that mitochondrial ROS
generation might be increased in MPECs in DH mice.
Indeed, as shown in Fig. 5, mitochondrial ROS concentra-
tion was significantly increased in MPEC isolated from
DH mice in comparison to cells isolated from CH mice.
Fig. 3. T2D mice exhibit an increase in pulmonary arterial branches and chronic hypoxia-exposure decreases vascular branches in both control
and T2D mice. (a) Representative angiography of the whole lung in control and T2D mice exposed to chronic normoxia or hypoxia. (b)
Summarized data showing the total length of branches, the number of branches, and the number of junctions of vascular segments per square
millimeter. CN, n¼ 6; DN, n¼ 7; CH, n¼ 4; DH; n¼ 5. Data are mean SEM. *P< 0.05 vs. CN.
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The increased mitochondrial ROS concentration in MPECs
from DH mice was associated with a significantly decreased
protein level of SOD2, an important dismutase that
decreases ROS level in the mitochondria (Fig. 5c). These
data suggest that downregulated SOD2 protein expression
level contributes to the increase in mitochondrial ROS con-
centration in MPEC of DH mice. The increased mitochon-
drial ROS in MPECs is, at least in part, responsible for the
attenuated EDR in PA of DH mice. Sustained inhibition of
endothelium-dependent pulmonary vasodilation then con-
tributes to the development and progression of severe PH
in diabetes under hypoxic conditions.
Discussion
Cardiovascular complications in diabetes are classified into
two major groups: microvascular diseases and macrovascu-
lar diseases. Microvascular diseases in diabetes include reti-
nopathy, nephropathy, and neuropathy; while
macrovascular complications in diabetes include stroke
and coronary heart disease. Therefore, the impacts of dia-
betes or high glucose on vascular function in the heart,
brain, kidney, retina, and peripheral arteries have been
extensively studied. It is, however, unclear whether diabetes
affects the function of PAs, especially whether diabetic vas-
cular endothelial dysfunction contributes to the develop-
ment and progression of PH. There is strong clinical
evidence showing that the development and/or progression
of PH are more prominent in diabetic patient compared to
control subjects,1–5,42 but the specific cellular mechanisms
potentially involved in the diabetes-associated severity of
PH has not been explored. It has to be noted that the clinical
reports investigating the relationship between PH and dia-
betes are all related to T2D, but not type 1 diabetes (T1D).
Feeding a HF diet in ApoE knockout mice induces insulin
resistance with mild, but significant, hyperglycemia. It was
shown that ApoE-KO mice with a HF diet exhibited a sig-
nificant increase in RVSP, right ventricular hypertrophy,
and muscularization of PAs.43 Kelley et al. also showed
that 20 weeks of HF treatment in mice increased plasma
insulin level that was associated with moderate increase of
plasma glucose; these mice also exhibited significantly aug-
mented RVSP, mean PAP, and pulmonary arterial
muscularization.44
In this study, we used two different T2D mouse models,
the inducible T2D mice and the genetically modified T2D
Fig. 4. (a, b) HighKþ-induced contraction is not different between PAs from CH and DH mice; however, EDR is significantly attenuated in DH-
PAs compared to CH-PAs. (a) HighKþ-induced pulmonary arterial contraction. n¼ 5 per group. Data are mean SEM. (b) ACh-induced
pulmonary arterial relaxation. CH, n¼ 7; DH, n¼ 6. Data are mean SEM. *P< 0.05 vs. CH. (c, d) Pretreatment of mitoTenhanced EDR in DH-
PAs, but not in CH-PAs. (c) ACh-induced pulmonary arterial relaxation in the presence and absence of mitoT in CH. n¼ 4 per group. Data are
mean SEM. (d) ACh-induced pulmonary arterial relaxation in the presence and absence of mitoT in DH. n¼ 4 per group. Data are mean SEM.
*P< 0.05 vs. CH.
Fig. 5. [ROS]mito is significantly increased and SOD2 protein expression is significantly decreased in MPECs from DH mice compared to CH
mice. (a) Cells were stained with MitoSOX (a mitochondrial ROS marker). (b) Summarized data showing [ROS]mito in CH and DH. CH, n¼ 155
cells; DH; n¼ 120 cells. Data are mean SEM. *P< 0.05 vs. CH. (c) Western blots showing SOD2 and actin protein levels (left panel). Actin was
used as a loading control. Right columns show SOD2 protein level normalized to actin. n¼ 5 per group. Data are mean SEM. *P< 0.05 vs. CH.
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mice (KK mice), to test pulmonary functions. Our inducible
T2D mice exhibited hyperglycemia, hyperinsulinemia,
hyperlipidemia, abnormal glucose tolerance, and impaired
insulin sensitivity.34,36 This is a well-established mouse
model to study T2D; the metabolic characteristics in this
model are very close to those in human T2D induced by a
Western diet.35,36,45–47
Under normoxic conditions, the inducible T2D mice and
the KK mice both exhibited severe impairment of glucose
tolerance. Chronic hypoxic exposure decreased fasting glu-
cose levels in all mouse groups; however, the impaired glu-
cose tolerance still remained in inducible T2D mice and KK
mice (Figs. 1b and 2b). The body weight was significantly
decreased in diabetic mice after hypoxic exposure (Figs. 1c
and 2c). The effect of hypoxia on weight loss has been
reported in humans and animals and it is more likely due
to increased metabolism by hypoxia.48–51
In agreement with the other investigator’s data, we also
found that the inducible T2D mice and the KK mice exhib-
ited slightly (but with statistical significance) increased
RVSP in comparison to the control mice (Figs. 1d, 1e and
2d, 2e). The most important and novel finding in this study
is that diabetes is a risk factor for developing severe PH in
mice. We demonstrate that chronic exposure to hypoxia
enhances the development and progression of PH in T2D
mice. Moral-Sanz et al. also demonstrated that T1D rats
exhibited the trend of enhanced hypoxia-induced PH (deter-
mined by hypoxia-induced increase in mean PAP) compared
to the control rats. Their observations also suggest that
macrophage infiltration is potentially an important mechan-
ism by which hyperglycemia inhibits pulmonary vasodila-
tion and ultimately leads to sustained pulmonary
vasoconstriction and development of severe PH under
hypoxic conditions.
PAP is a function of cardiac output (CO) and PVR. In
patients and animals with hypoxia-induced PH, CO is not
significantly augmented indicating that the increased PAP is
mainly due to increased PVR. PVR is inversely proportional
to the fourth power of intraluminal radius or diameter of
PAs, so a very small decrease in intramural radius/diameter
in PAs and arterioles would significantly increase PVR and
PAP. The major causes that directly lead to increased PVR
are thus sustained pulmonary vasoconstriction, concentric
pulmonary vascular wall thickening, in situ thrombosis, and
increased pulmonary vascular wall stiffness.
As shown in Fig. 3c, chronic hypoxia significantly
decreased the pulmonary arterial branches which is expected
from the data of increased RVSP under hypoxia in Fig. 1.
However, there is no significant different between control
mice exposed to hypoxia (CH) and T2D exposed to hypoxia
(DH), suggesting that the significant difference of RVSP
between CH and DH is not because of the change in pul-
monary vascular branches.
Vascular tension is regulated by vasoconstriction and
vasodilation; increased vascular constriction and decreased
vascular relaxation lead to increased vascular tension. It has
been demonstrated that EDR in patients with T2D and
animals with experimental T2D is attenuated in various vas-
cular systems;10–12,14,15 however, it is still controversial
whether pulmonary EDR is attenuated52–55 or not chan-
ged56,57 in animals with experimental HPH. The data from
this study (Fig. 4a) demonstrated that high-Kþ induced con-
traction in PAs isolated from DH mice was not altered in
comparison to PAs isolated from CH mice. However, EDR
in isolated PAs was significantly impaired in DH mice com-
pared to CH mice (Fig. 4b) or to CN and DN mice (supple-
mental data 1). Importantly, the attenuated pulmonary
arterial EDR in DH mice could be rescued by pretreatment
of the DH PAs with mitoT, a mitochondrial O2
– scavenger.
These results strongly suggest that excessive production of
O2
– in the mitochondria during hypoxia is an important
mechanism involved in the inhibition of pulmonary arterial
EDR in DH mice. By directly measuring ROS in mitochon-
dria (Fig. 5a and 5b), we further confirmed that MPECs
isolated from DH mice exhibited significantly higher level
of [ROS]mito compared with MPECs isolated from CH mice.
Increased ROS production in mitochondria has been
implicated in endothelial dysfunction in diabetes.24,27,28,34
We also observed a significant increase in [ROS]mito in dia-
betic MPECs compared to control MPECs under normoxia
(supplemental data 2). Whether [ROS]mito is increased or
decreased during hypoxia or in hypoxia-induced PH is, how-
ever, still controversial. While some report that [ROS]mito is
increased in PH,32,58,59 some indicate that [ROS]mito is
decreased in PH.60–62 In the current study, we showed that
chelation of mitochondrial ROS with mitoT (by pretreating
the isolated pulmonary arterial rings with mitoT) did not
affect EDR in PAs isolated from CH mice. These data sug-
gest that mitochondrial ROS production is not excessive
enough in the HPH model to attenuate EDR in PAs. The
mouse lung or the lung vasculature seems to have sufficient
capacity to efficiently eliminate ROS in the mitochondria
under hypoxic conditions in control mice. In diabetic mice
exposed to chronic hypoxia, however, mitochondrial ROS
production seems to be excessive enough to inhibit pulmon-
ary arterial EDR.
Mitochondrial O2
 is largely released to the matrix at
complex I and to the intermembrane space at complex III in
the electron transport chain. SOD catalyzes the dismutation
of O2
 to hydrogen peroxide (H2O2). H2O2 is detoxified to
H2O in the matrix by catalase, the thioredoxin/thioredoxin
peroxidase system, or the glutathione/glutathione peroxi-
dase system. SOD2 is predominantly expressed in mitochon-
dria, whereas SOD1 is expressed mainly in the cytoplasm.
SOD2 protein expression is decreased in ECs34 or arteries63
in T2D mice. Our results from this study indicated that
MPECs isolated from DH mice exhibited significantly
lower expression level of SOD2 compared to CH mice.
These data suggest that the downregulated SOD2 expression
is one of the causes to increase mitochondrial ROS and,
subsequently, attenuate EDR in PAs isolated from chroni-
cally hypoxic mice with T2D. The question is whether
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scavenging mitochondrial O2
 is able to prevent the devel-
opment of severe HPH in diabetes. Adesina et al. demon-
strated that overexpression of mitochondria-tagged catalase,
but not SOD2, decreased RVSP in chronically hypoxic mice,
suggesting that decreasing mitochondrial [O2
] and elimi-
nating O2
 byproduct, H2O2, are both required to prevent
the development of HPH.32 Although our data show that
mitoT sufficiently restores EDR in PAs isolated from DH
mice toward the level similar to the PAs isolated from CH
mice, it is possible that the treatment with SOD/catalase
mimetic agents (e.g. EUK134, EUK207) would further
improve EDR in DH mice and restore the inhibited EDR
toward the level similar to the PAs isolated from CN mice.
In our angiography experiments (Fig. 3), it was unex-
pected to observe the significant increase of the numbers
of pulmonary vascular branches and junctions in DN mice
in comparison to CN mice (Fig. 3). An increased number of
vascular branches should lead to a reduction of vascular
resistance and a decrease in RVSP if other parameters are
not altered (e.g. vascular reactivity). If PAs and/or arterioles
are more prone to contraction because of inhibited EDR in
diabetes, the effect of increased vascular branches and junc-
tions on RVSP could be masked by decreased intraluminal
radius. We found that there was a trend of decrease in EDR
in DN mice compared to CN mice, although no statistical
significance was achieved (supplemental data 1), suggesting
that there might be another mechanism to explain the higher
RVSP in DN compared to CN. We need to conduct further
experiment to define the molecular mechanisms in which
RVSP was significantly increased in DN compared to CN.
In conclusion, we demonstrate that diabetic mice are
more susceptive to hypoxia and develop severe HPH due,
at least in part, to the downregulation of SOD2, increase in
[ROS]mito in MPECs, and inhibition of EDR in PAs in
hypoxia-exposed diabetic mice compared to hypoxia-
exposed control mice. These data also suggest that patients
with diabetes are susceptible to pulmonary vascular disease
associated with hypoxia.
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